Evidence map›Paper›PMID 39415301›Full record

ArticleJournal of medical case reports2024

Successful administration of cetuximab using dose escalation method: a case report.

Shasha Li, Yanjuan Zhang, Jiandong Zha, Wenqi Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shasha LiDepartment of Clinical Oncology, The University of Hong Kong Shenzhen Hospital, Shenzhen, China. liss7@hku-szh.org.
Yanjuan ZhangDepartment of Pharmacy, The University of Hong Kong Shenzhen Hospital, Shenzhen, China.
Jiandong ZhaDepartment of Clinical Oncology, The University of Hong Kong Shenzhen Hospital, Shenzhen, China.
Wenqi ChenDepartment of Clinical Oncology, The University of Hong Kong Shenzhen Hospital, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCetuximab, used to treat head and neck squamous cell carcinoma and metastatic colorectal cancer, can cause severe infusion reactions. CASE PRESENTATION: We report an 87-year-old East Asian woman with stage IV ileocecal signet ring cell carcinoma who experienced severe allergic reactions to cetuximab despite pre-treatment. A dose escalation method, involving weekly incremental doses with comprehensive pre-treatment and close monitoring, was employed, successfully reducing allergic reactions and allowing safe administration.

conclusionThis approach demonstrates a viable alternative for patients with hypersensitivity to cetuximab, warranting further research for personalized treatment optimization.

Indexed as

Antineoplastic Agents, ImmunologicalCetuximabAged, 80 and overCarcinoma, Signet Ring CellCecal NeoplasmsDose-Response Relationship, DrugDrug HypersensitivityFemaleHumansTreatment OutcomeAntineoplastic Agents, ImmunologicalCetuximabCase reportCetuximabDesensitizationDose escalationHypersensitivityInfusion reaction

Identifiers

PMID39415301
PMCPMC11484190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.